Article
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
British journal of haematology - 1 Apr 2024
Tefferi Ayalew, Fleti Farah, Chan Onyee, Al Ali Najla H, Al-Kali Aref, Begna Kebede H, Foran James M, Badar Talha, Khera Nandita, Shah Mithun, Hiwase Devendra, Padron Eric, Sallman David A, Pardanani Animesh, Arber Daniel A, Orazi Attilio, Reichard Kaaren K, He Rong, Ketterling Rhett P, Gangat Naseema, Komrokji Rami
Abstract excerpt
Among 210 patients with myelodysplastic syndromes (MDSs) with del(5q), molecular information was available at diagnosis or at least 3 months before leukaemic transformation in 146 cases. Multivariate analysis identified therapy-related setting (p = 0.02; HR 2.3) and TP53 variant allele frequency (VAF) ≥22% (p < 0.01; HR 2.8), but not SF3B1 mutation (p = 0.65), as independent risk factors for survival. Median...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.